Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic.

Obesity (Silver Spring) · 2021 · PMC8168710 · PMID 33759389

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a positive trendP = 0.07so close (0.05 < p ≤ 0.1)

The weight loss for each medication at 12 months in the phenotype‐guided group compared with the non‐phenotype‐guided group was statistically significant for phentermine‐topiramate extended release, lorcaserin, and liraglutide; there was a positive trend for bupropion‐naltrexone sustained release ( P = 0.07) (Supporting Information Figure S3 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.